INFANT MORTALITY IN THE RURAL HLABISA HEALTH DISTRICT — ESTIMATION USING THE PREVIOUS BIRTH TECHNIQUE

To the Editor: The infant mortality rate (IMR) is recognised as being a key health factor indicator. However, owing to a lack of appropriate surveys there are few reliable estimates of the IMR in rural South Africa. Estimates of the IMR range from 15 to 71 per 1 000 total births, depending on setting and methodology used.1

One validated methodology is the ‘previous birth technique’, in which women attending antenatal clinics are asked about their previous birth experience. Those with a previous live birth are asked whether that child is still alive, and the West model life table is used to estimate the IMR from these data (D Bradshaw — unpublished report, Medical Research Council). The same tables provide estimates of the under-5 mortality rate.

Hlabisa health district in rural northern KwaZulu-Natal is home to approximately 250 000 Zulu-speaking people. The Hlabisa Nursing Service provides a mobile primary health care service through 16 mobile clinic points across the district. Our previous work2 suggests that these clinics serve a population representative of the district as a whole. A previous survey indicates that approximately 95% of pregnant women in the district receive antenatal care.3

For a 1-year period ending July 1998, all women attending the clinics for antenatal care were asked about their previous birth experience. Of 708 women whose last baby had been born alive, 42 reported that child to have since died. The estimated IMR is therefore 53 per 1 000 total births (95% confidence interval (CI) 42 - 71), and the under-5 mortality rate is estimated at 70 per 1 000 population (95% CI 53 - 98).

These are the first estimates of the IMR and the under-5 mortality rate in Hlabisa. They provide an important baseline against which changes in health status can be measured. It is predicted that the HIV epidemic is having a substantial impact on infant mortality in Africa.4 The relatively high rate reported here may already reflect this in part, as the HIV epidemic and its impact is already well established in KwaZulu/Natal. Simple and cheap survey methodologies such as this can provide important information on health status.

David Wilkinson
Centre for Epidemiological Research in South Africa
Medical Research Council
P O Box 187
Mtubatuba
3933

Marlene Sach
Hlabisa Nursing Service
Hlabisa, KwaZulu-Natal


DS/17 IN OBSESSIVE-COMPULSIVE DISORDER AND TRICHOTILLOMANIA

To the Editor: The finding that patients with Sydenham’s chorea often demonstrate obsessive-compulsive disorder (OCD) has fostered increased interest in possible neuro-immunological mechanisms in OCD.1 Increased expression of the B-lymphocyte antigen DS/17, which has been hypothesised to be a genetically inherited trait marker for susceptibility to rheumatic fever, has recently been demonstrated to be higher in OCD patients than in normal controls.2 To date, however, DS/17 expression has been studied in few psychiatric control populations.

Some authors have suggested that trichotillomania (TTM) is related to OCD insofar as it involves repetitive ritualistic behaviours and responds selectively to the serotonin reuptake inhibitor, clomipramine.3 Nevertheless, there are also many phenomenological and neurobiological differences between OCD and TTM.4 Of note, however, is a case report of Sydenham’s chorea associated with hair-pulling,5 and reports that TTM may be exacerbated after streptococcal infection.6

We assessed DS/17 expression in 17 TTM patients (3 male, 14 female), 12 OCD patients (4 male, 8 female), and 22 normal controls (9 male, 12 female). All subjects were adults of Afrikaner descent. Eight of the 12 OCD patients and 14 of 17 TTM patients had onset of symptoms in childhood or adolescence. The Structured Clinical Interview for Axis I Disorders (SCID-I) was used to diagnose patients, and to exclude current or past psychiatric disorders in controls. DS/17 expression was measured using an indirect immunofluorescence assay, as described elsewhere.7

Analysis of variance of DS/17 levels showed a significant group difference (F = 4.06, P = 0.02). The average percentage of B cells expressing the DS/17 antigen was found to be significantly higher in patients with OCD (29.2 ± 15.0%) than in either TTM patients (16.6 ± 13.6%, P = 0.03) or controls (17.9 ± 10.5%, P = 0.02). Similarly, positive DS/17 expression (defined as having 12% or more DS/17+ cells) appeared more common in those with OCD (11/12) than in either TTM patients (10/17, P = 0.06) or controls (14/22, P = 0.08), although there was only a trend towards statistical significance.

1. OCD) has fostered increased interest in possible neuro-immunological mechanisms in OCD.1 Increased expression of the B-lymphocyte antigen DS/17, which has been hypothesised to be a genetically inherited trait marker for susceptibility to rheumatic fever, has recently been demonstrated to be higher in OCD patients than in normal controls. To date, however, DS/17 expression has been studied in few psychiatric control populations.

Some authors have suggested that trichotillomania (TTM) is related to OCD insofar as it involves repetitive ritualistic behaviours and responds selectively to the serotonin reuptake inhibitor, clomipramine. Nevertheless, there are also many phenomenological and neurobiological differences between OCD and TTM. Of note, however, is a case report of Sydenham’s chorea associated with hair-pulling, and reports that TTM may be exacerbated after streptococcal infection.

We assessed DS/17 expression in 17 TTM patients (3 male, 14 female), 12 OCD patients (4 male, 8 female), and 22 normal controls (9 male, 12 female). All subjects were adults of Afrikaner descent. Eight of the 12 OCD patients and 14 of 17 TTM patients had onset of symptoms in childhood or adolescence. The Structured Clinical Interview for Axis I Disorders (SCID-I) was used to diagnose patients, and to exclude current or past psychiatric disorders in controls. DS/17 expression was measured using an indirect immunofluorescence assay, as described elsewhere.

Analysis of variance of DS/17 levels showed a significant group difference (F = 4.06, P = 0.02). The average percentage of B cells expressing the DS/17 antigen was found to be significantly higher in patients with OCD (29.2 ± 15.0%) than in either TTM patients (16.6 ± 13.6%, P = 0.03) or controls (17.9 ± 10.5%, P = 0.02). Similarly, positive DS/17 expression (defined as having 12% or more DS/17+ cells) appeared more common in those with OCD (11/12) than in either TTM patients (10/17, P = 0.06) or controls (14/22, P = 0.08), although there was only a trend towards statistical significance.
These findings indicate that there may be differences in any possible neuro-immunological mechanisms underlying OCD and TTM. However these findings need to be qualified by emphasising the small sample size used, and by noting the possibility that there may be an overlap between OCD and a particular subgroup of TTM. While the mean percentage of B cells expressing D8/17 in OCD found here was similar to that noted in previous work on childhood-onset OCD, the relatively high levels obtained in both our controls and TTM patients may indicate that this is not an uncommonly expressed antigen in certain population groups, such as among Afrikaners.


MRC Research Unit on Anxiety Disorders
Department of Psychiatry
University of Stellenbosch
Tygerberg, WCape


Expert guidance — on the spot . . .

How should you treat a patient who presents with complications of chemotherapy? If your patient has persistent convulsive seizures, what treatment should you pursue? What side-effects are associated with beta-adrenergic antagonists in hypertension? What should you do if your patient goes into shock? What antiretroviral agents should you give patients with newly diagnosed HIV? Which drugs should be avoided during the first trimester of pregnancy?

The Washington Manual of Medical Therapeutics
29th edition
Department of Internal Medicine, Washington University School of Medicine
April 1998. 600 pp, illustrated, R142.50

For nearly 50 years, Washington University’s Manual of Medical Therapeutics has been the standard reference in medical wards and practices in the USA and elsewhere internationally. Now the Washington Manual of Medical Therapeutics has been made available to South African medical practitioners at almost half the normal US dollar price. This 29th edition features an easy-to-use outline format, authoritative guidance to current management of common medical disorders, and local organisation by body system. From initial patient presentation through step-by-step diagnostic and treatment procedures, the manual gives you all the information you need to make smart decisions. Focusing on the latest standards of therapy and care, it provides in a concise, user-friendly way, the key information you need to provide state-of-the-art quality care for your patients.

Order your copy from the SA Medical Association (Multimedia), Private Bag X1, Pinelands 7430, tel (021) 531-3081, fax (021) 531-4126, e-mail: jstrydom@samedical.co.za
Prepayment is required. Ample stock is held in Cape Town. Please allow 1 - 2 weeks for postal delivery.